USA flag logo/image

An Official Website of the United States Government

5-Day Fiber-Coupled Fluorescense Sensor for Interstitial Glucose Monitoring

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80263
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK076352
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOTEX, INC.
8058 EL RIO ST HOUSTON, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: 5-Day Fiber-Coupled Fluorescense Sensor for Interstitial Glucose Monitoring
Agency: HHS
Contract: 2R44DK076352-02A2
Award Amount: $788,637.00
 

Abstract:

DESCRIPTION (provided by applicant): There is an urgent need for a long-term in vivo glucose-monitoring device for diabetes therapy. Diabetes is currently believed to afflict over 100 million people worldwide and nearly 18 million in the United States. In the U.S. this disorder, along with its associated complications, is ranked as the seventh leading cause of death. Research indicates that these long-term complications can be minimized in diabetics if blood glucose levels are maintained as near normal leve ls (60-110 mg/dL) as possible, so called tight glucose control. The integration of continuous glucose monitor readings into an automatic insulin pump control algorithm may substantially increase both the safety and effectiveness of insulin therapy in dia betics. BioTex, Inc. has developed a superior fluorescence affinity glucose sensor which is one of the most promising technologies currently being pursued for application in diabetes research and therapy. The objective this Phase II proposal is to commence human clinical studies with the sensor under an investigational device exemption (IDE) from the FDA. The anticipated outcome will be a thorough characterization of the optimal implantation, instrumentation, and use of the sensor in humans and refinements of the associated accessories and procedures. At the end of this project we will be poised to commence larger human clinical trials in support of a pre-market approval (PMA) application to the FDA for marketing a 3-5 day implantable continuous glucose sens ing system. PUBLIC HEALTH RELEVANCE: BioTex, Inc. has successfully developed a minimally-invasive fluorescence affinity sensor (FAS) for continuous glucose monitoring over 3-5 days. The FAS has a number of advantages over currently available short-term imp lantable glucose sensors and is expected be a significant tool for diabetes research and therapy. Diabetes currently afflicts over 100 million people worldwide and nearly 18 million in the United States, and this disorder, along with its associated complic ations, is ranked as the seventh leading cause of death.

Principal Investigator:

Ralph Ballerstadt
7137410111
RALPH@BIOTEXMEDICAL.COM

Business Contact:


ashok@biotexmedical.com
Small Business Information at Submission:

BIOTEX, INC.
BIOTEX, INC. 8058 EL RIO ST HOUSTON, TX 77054

EIN/Tax ID: 742824041
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No